Patrick Reichl
Toxicologist and Non-Clinical Consultant
Patrick Reichl is a non-clinical consultant with extensive experience in the pharmaceutical and medical device industries. He is a European Registered Toxicologist (ERT) with a PhD in Biology and a Master’s degree in Toxicology. He began his career as a Toxicological Risk Assessor at Baxter and later served as Toxicology Lead at Croma Pharma before transitioning to independent consulting and founding ATGC e.U. in 2025. His expertise includes in silico toxicology, genotoxicity assessment as well as the evaluation of devices, excipients, materials and impurities, with a focus on developing non-clinical strategies to support global regulatory submissions.
DAY 2: December 5th, 2025
SESSION: Toxicological Risk Assessment of Impurities in Medical Devices
◆ Regulatory updates in the new ISO 10993-1 and impact on toxicological risk assessment.
◆ Practical challenges in applying ISO 10993-17:2023 for medical devices.
◆ Case studies.
DAY 2: December 5th, 2024
SESSION: Chemical Characterization and Toxicological Risk Assessment of Genotoxic Impurities in Medical Devices
◆ Establishment of the Analytical Evaluation Threshold (AET) for an implantable, absorbable medical device.
◆ Conducting in silico assessments of potential genotoxic impurities.
◆ Addressing recent regulatory developments and navigating associated challenges.
DAY 2: December 1st, 2023
SESSION: Genotoxic impurities in medical devices
◆ Regulatory framework for GIs in Medical Devices.
◆ Recent developments (ISO 10993-17:2023).
◆ Case studies.
DAY 2: December 3rd, 2012
SESSION: Genotoxic impurities in medical devices
◆ Regulatory framework for GIS in Medical Devices.
◆ Recent developments.
◆ Case studies.
